Literature DB >> 14689084

[Hypercalcemic crisis].

J Pfeilschifter1.   

Abstract

Severe hypercalcemia is a life-threatening medical emergency. It is most commonly caused by malignant tumors, but can also be caused by primary hyperparathyroidism or less often by a dysregulated production of active vitamin D in granulomatous disorders. Symptoms include nausea, vomiting, renal insufficiency, severe dehydration, lethargy, confusion, and even coma. Severity of symptoms, calcium concentrations, and the overall status of the patient are important considerations in selecting appropriate therapy. Hydration to correct volume depletion is the cornerstone of acute therapy. Loop diuretics may be added to saline hydration after extracellular fluid volume has been replenished to enhance urinary calcium excretion and mitigate fluid overload from rehydration. Calcitonin and intravenous infusion of bisphosphonates reduce serum calcium levels by interfering with calcium release from the skeleton. Dialysis with a low or zero calcium dialysate is reserved for patients who are refractory to these measures. Corticosteroids are effective with hypercalcemia due to increased vitamin D levels and in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14689084     DOI: 10.1007/s00108-003-1048-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  21 in total

1.  [Acute renal failure due to hypercalcemia and peripheral polyneuropathy--rare manifestations of sarcoidosis].

Authors:  A Dierkes-Globisch; W Schneiderhan; H H Mohr
Journal:  Med Klin (Munich)       Date:  2000-10-15

Review 2.  Management of acute hypercalcemia.

Authors:  J P Bilezikian
Journal:  N Engl J Med       Date:  1992-04-30       Impact factor: 91.245

3.  Longitudinal studies of mild primary hyperparathyroidism.

Authors:  S Ljunghall; S Jakobsson; C Joborn; M Palmér; J Rastad; G Akerström
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

4.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 5.  [Differential diagnosis of hypercalcemia in adults].

Authors:  J Pfeilschifter; H Schatz
Journal:  Med Klin (Munich)       Date:  2000-03-15

Review 6.  Hypercalcemia in granulomatous disorders: a clinical review.

Authors:  O P Sharma
Journal:  Curr Opin Pulm Med       Date:  2000-09       Impact factor: 3.155

7.  Calcium free hemodialysis: experience in the treatment of 33 patients with severe hypercalcemia.

Authors:  C Camus; C Charasse; I Jouannic-Montier; P Seguin; Y L Tulzo; J Bouget; R Thomas
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

8.  Acute primary hyperparathyroidism.

Authors:  L A Fitzpatrick; J P Bilezikian
Journal:  Am J Med       Date:  1987-02       Impact factor: 4.965

9.  Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia?

Authors:  S Shah; Janet Hardy; E Rees; J Ling; B Gwilliam; C Davis; K Broadley; R A'Hern
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

Review 10.  Bone disease in myeloma.

Authors:  J R Berenson
Journal:  Curr Treat Options Oncol       Date:  2001-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.